MedTrace Logo

Effectiveness of PRP Pharmacopuncture for Chronic Neck Pain in Cervical Myofascial Syndrome of the Upper Trapezius

NCT07119255 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-16

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether pharmacopuncture with Platelet-Rich Plasma (PRP) is effective for treating chronic neck pain in cervical myofascial syndrome related to the upper trapezius muscle. The main questions it aims to answer are:

1. Is pharmacopuncture with Platelet-Rich Plasma (PRP) effective in reducing chronic neck pain in patients with cervical myofascial syndrome related to the upper trapezius muscle?
2. Does PRP pharmacopuncture improve functional outcomes and quality of life in these patients?
3. Are there any adverse effects associated with PRP pharmacopuncture in this context?

Researchers will compare PRP pharmacopuncture to normal saline pharmacopuncture (placebo) to evaluate whether PRP provides greater effectiveness in reducing chronic neck pain in cervical myofascial syndrome related to the upper trapezius muscle.

Participants will:

* Receive a single session of pharmacopuncture therapy
* Undergo evaluations at week 2, week 4, and week 8 after the intervention

Conditions

  • Neck Pain
  • Myofascial Pain Syndrome

Interventions

PROCEDURE

PRP Pharmacopuncture

Participants in the PRP pharmacopuncture arm will receive a single administration of platelet-rich plasma (PRP) via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.

PROCEDURE

Placebo Pharmacopuncture

Participants in the placebo pharmacopuncture arm will receive a single administration of normal saline via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • KEPK FKUI-RSCM · The Ethics Committee of the Faculty of Medicine, University of Indonesia - RSCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07119255 on ClinicalTrials.gov